Have Questions? Call Us Toll Free (877) 880-5251

Lucentis slows progression of diabetic retinopathy

A three-year study reveals that a drug used to treat macular degeneration may also be effective in slowing the progression of diabetic retinopathy. The study was conducted at the University of Wisconsin and researchers evaluated the use of Lucentis to help treat diabetic retinopathy. 700 people participated in the study and researchers determined that not only did Lucentis help slow the progression of the disease it also improved the visual acuity of patients. Earlier this year, the Food and Drug Administration approved Lucentis for the treatment of diabetic macular edema, which actually develops from diabetic retinopathy. Diabetic retinopathy is the most common eye disease afflicting diabetics with 40 to 45 percent of people with diabetes having some level of the disease. More research is needed and researchers would also like to see if it would be possible to reduce the need for monthly injections but still maintain the same level of efficacy.*  

Search VisiVite